| Just Other Articles |
Hubs | Hubbers | Topics | Request |
| #1 in Business | Subscribe Email Print |
|
You are here: Home > Business > Business > Innovation Expenses - Finding the Right Balance |
|
Just Other Articles - Innovation Expenses - Finding the Right Balance
Think a moment about the journalist and the historian. The former is presenting the new According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product (s) the latter combines the new into a (historic) perspective. If you want to be in th ; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug. Examples of combination products may in lead with new trends like the innovator you should know the new(s). You should know ab lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together. out all new developments and more important, you should try and proof them. This is mor here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe than a single experiment with new technology. Blogging for example is such a new trend d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations. Combination pro , and the innovator (journalist) will experiment with it. Like the investment journali ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc t who is commenting on a financial movement during the day, the innovator will not be a easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi ble to determine in what direction the trend will go, nor whether the new movement is s nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically rong enough to be a real trend. The more conservative investor and entrepreneur will w and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ ait to take action on all those pre-trend movements. He wants to value the new movement ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi before betting his money on it. To do this you need to put things into (historic) persp ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it. Following aspects would a ective. The approach of the innovator brings advantage in the sense that he is up to d dd to the challenges in developing combination products: Which markets to tap where the combination products can do fairly well? Which combination prod te, and gains hands on experience on the matter. The disadvantage is that each such an cts are meaningful and rational? Which therapeutic categories to select? Which Combinations can address unmet needs of the patients? Do combin experience costs time and money that could have been spent otherwise. But once one of t tions increase the patient compliance? What would be the developing cost? How to tackle the risks encountered during combination product developmen e little trends is speeding up, the innovator is already there standby to take the next t? As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel steps. The conservative entrepreneur will be affected by this new development and nee ping new procedures for reviewing their safety, efficacy and quality. Professional from academic institutions, pharmaceutical industries, health care indust s to redefine his strategy according to the impact on his market. He is not experienced y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products with the new trends or technology and needs to catch-up with the pioneers. The real q . As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de estion is what is more expensive - all those little experiments for which many will not elopment. They need to be wiser in analyzing the market trends and the regulatory requirements. Companies that provide selfless information through particip survive, or to wait until a real significant development is manifest. © 2006 Hans Boo tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
Related Articles:Six Ways to Succeed in Business Medical Billing - Choosing A Carrier
|